Has Wendell Miers, MD received payments from drug or device companies?

Yes. Drug and device makers reported $181,645 in general payments to Wendell Miers, MD across 648 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wendell Miers, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wendell Miers, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wendell Miers, MD

Endocrinology, Diabetes & Metabolism · Lexington, KYNPI 1356403489

Payments from drug & device makers

$181,645in general payments, 2019–2025

Across 648 payments — averaging $280.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$105K
AbbVie$33K
Novo Nordisk$25K
Janssen Research & Development, LLC$6K
Johnson & Johnson$4K
Boehringer Ingelheim$745
plus $8K from 41 others

$9,437in research payments, 2019–2025

Across 5 payments — averaging $1887.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$9K
AbbVie$616

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	12	$104,876
AbbVie(2 entities)	32	$33,048
Novo Nordisk	119	$24,870
Janssen Research & Development, LLC	2	$5,775
Johnson & Johnson	12	$4,428
Boehringer Ingelheim	55	$745
AstraZeneca(2 entities)	48	$732
Dexcom, Inc.	20	$722
Mannkind Corporation	46	$693
Abbott	37	$662
Medtronic(2 entities)	24	$609
Bayer	15	$595
Sanofi-aventis U.S. LLC	32	$434
Amarin Pharma, Inc.	27	$432
Lilly USA, LLC	19	$309
Amgen(2 entities)	15	$247
Insulet Corporation	12	$239
Tandem Diabetes Care, Inc.	9	$236
Xeris Pharmaceuticals, Inc.	11	$228
Antares Pharma, Inc.	8	$196
Merck	20	$195
Corcept Therapeutics	6	$184
Esperion Therapeutics, Inc.	11	$140
Zealand Pharma US, Inc.	9	$126
Ascendis Pharma Endocrinology Inc	2	$120
BD	4	$94
Radius Health, Inc.	4	$69
Amryt Pharma Holdings Ltd	4	$69
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	4	$59
Amneal Pharmaceuticals LLC	3	$56
IBSA Pharma Inc.	4	$55
Tolmar, Inc.	2	$48
BETA Bionics, Inc.	2	$44
Halozyme Inc	2	$43
Takeda Pharmaceuticals U.S.A., Inc.	3	$38
Shire North American Group Inc	2	$32
Sequel Med Tech, LLC	1	$30
Almatica Pharma LLC	1	$26
Senseonics, Incorporated	1	$21
Neurocrine Biosciences, Inc.	1	$21
Lifescan, Inc.	1	$19
Kyowa Kirin, Inc.	1	$17
Recordati_rare_diseases_inc.	1	$16
Azurity Pharmaceuticals, Inc.	1	$15
Ultragenyx Pharmaceutical Inc.	1	$15
Kowa Pharmaceuticals America, Inc.	1	$12
Advanced Oxygen Therapy Inc.	1	$7

How this compares

$181,645 in reported general payments places this provider in the 90th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky →

Medicare billing

Part B allowed, 2024

$116,811

Medicare patients

545

Services billed

2,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Lexington

Lyle MyersLexington$434K
Dennis KarounosLexington$212K
Kenneth AinLexington$166K
Leera PatelLexington$34K
Simon FisherLexington$26K
Anna MarinoLexington$23K
Gordon GuthrieLexington$14K
Megan MinchLexington$4K
Walaa AyoubLexington$3K
Kristina HumphriesLexington$3K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →